Lin Qian, Cai Beichen, Chen Lu, Wan Xiaofen, Ke Ruonan, Ni Xuejun, Shan Xiuying, Wang Biao
Department of Plastic Surgery, The First Affiliated Hospital of Fujian Medical University, No. 20, Chazhong Road, Taijiang District, Fuzhou, China.
Department of Plastic Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, No. 999, Huashan Road, Fuzhou, Changle District, China.
Aesthetic Plast Surg. 2025 Jan 2. doi: 10.1007/s00266-024-04633-7.
Bromhidrosis significantly impacts individuals' social, professional, and emotional well-being. Traditional treatments such as en bloc excision and alcohol injections are now less favored due to associated complications and suboptimal outcomes. Current evidence identifies botulinum toxin A (BTX-A) as the first-line treatment for mild to moderate cases (Grade 0-2), attributed to its high efficacy, excellent safety profile, and minimally invasive nature. BTX-A achieves effectiveness rates exceeding 90%, with results persisting for 3-8 months. A standardized grading system guides treatment selection, reserving surgical interventions for severe cases (Grade 3) or situations where BTX-A is contraindicated. Modern surgical approaches, such as hydrosurgery and endoscopic-assisted procedures, have shown improved outcomes and significantly fewer complications compared to traditional methods. Energy-based therapies, including laser, radiofrequency, and microwave treatments, also provide viable alternatives for patients unsuitable for BTX-A, demonstrating documented efficacy and minimal invasiveness. This review proposes an evidence-based treatment algorithm for bromhidrosis management, highlighting the central role of BTX-A while detailing alternative strategies. The framework integrates disease severity assessment, patient preferences, and cost considerations to support optimal clinical decision-making. By adopting this systematic approach, clinicians can enhance treatment selection and improve patient outcomes.Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
臭汗症对个人的社交、职业和情感幸福有着显著影响。诸如整块切除和酒精注射等传统治疗方法,由于相关并发症和欠佳的治疗效果,如今已不太受青睐。目前的证据表明,肉毒杆菌毒素A(BTX-A)是轻度至中度病例(0-2级)的一线治疗方法,这归因于其高效、良好的安全性和微创性。BTX-A的有效率超过90%,效果可持续3至8个月。一个标准化的分级系统指导治疗方案的选择,对于严重病例(3级)或BTX-A禁忌的情况则保留手术干预。与传统方法相比,现代手术方法,如水刀手术和内镜辅助手术,已显示出更好的治疗效果和显著减少的并发症。基于能量的治疗方法,包括激光、射频和微波治疗,也为不适合使用BTX-A的患者提供了可行的替代方案,显示出已证实的疗效和微创性。本综述提出了一种基于证据的臭汗症治疗算法,突出了BTX-A的核心作用,同时详细介绍了替代策略。该框架整合了疾病严重程度评估、患者偏好和成本考量,以支持最佳临床决策。通过采用这种系统方法,临床医生可以优化治疗选择并改善患者治疗效果。证据级别V 本刊要求作者为每篇文章指定证据级别。有关这些循证医学评级的完整描述,请参阅目录或作者在线指南www.springer.com/00266 。